We are live on ! Find out more
HAE icon

Haemonetics

181 hedge funds and large institutions have $1.88B invested in Haemonetics in 2016 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 67 increasing their positions, 63 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

27% more capital invested

Capital invested by funds: $1.48B → $1.88B (+$394M)

14% more first-time investments, than exits

New positions opened: 25 | Existing positions closed: 22

2% more funds holding

Funds holding: 178181 (+3)

6% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 63

0.98% more ownership

Funds ownership: 100.03%101.01% (+0.98%)

0% more funds holding in top 10

Funds holding in top 10: 33 (0)

Holders
181
Holders Change
+3
Holders Change %
+1.69%
% of All Funds
4.82%
Holding in Top 10
3
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
0.08%
New
25
Increased
67
Reduced
63
Closed
22
Calls
$449K
Puts
Net Calls
+$449K
Net Calls Change
+$200K

HAE Hedge Fund Activity: Q3 2016 in Review

181 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Haemonetics (HAE) for Q3 2016, worth a combined $1.88B — up 27% from $1.48B a quarter earlier.

Buyers outnumbered sellers: 25 funds opened new HAE positions and 22 closed out — a net gain of 3 holders — while 67 added to existing stakes and 63 trimmed.

The largest buyer was Wellington Management Group, adding an estimated $30.2M. The largest seller was Black Creek Investment Management, cutting an estimated $22.7M.

  • 181 institutional investors held Haemonetics (HAE) as of Q3 2016, up from 178 in Q2 2016.
  • Funds reported $1.88B of Haemonetics stock for Q3 2016, up 27% quarter-over-quarter.
  • 25 funds opened new Haemonetics positions in Q3 2016 and 22 closed out, a net change of +3 holders.
  • The largest Haemonetics buyer in Q3 2016 was Wellington Management Group, an estimated $30.2M added.
  • The largest Haemonetics seller in Q3 2016 was Black Creek Investment Management, an estimated $22.7M sold.

Based on aggregated 13F filings for Q3 2016.